izpis_h1_title_alt

Pharmaceutical product liability, litigation regimes, and the propensity to patent : an empirical firm-level investigation
Kovač, Mitja (Avtor), Datta, Salvini (Avtor), Spruk, Rok (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (397,74 KB)
MD5: 7E3DA0CD6E80ECDCCED4393861A883AF
URLURL - Predstavitvena datoteka, za dostop obiščite https://journals.sagepub.com/doi/10.1177/21582440211009470 Povezava se odpre v novem oknu

Izvleček
Do different pharmaceutical product liability regimes in different countries induce propensity to patent? We exploit the variation in pharmaceutical liability and litigation rules across firms in the pharmaceutical industry and countries to explain the firm-level propensity to patent. Drawing on a large dataset from European Patent Office (EPO) covering over 9,950 pharmaceutical patents from 63 countries over the period 1991–2015, we compute the conditional probabilities of individual pharmaceutical firms to acquire a valid-based patent on the validation outcomes and examine whether different liability regimes encourage or deter firm-level propensity to patent. Our empirical strategy addresses firm-level idiosyncrasies, country-level unobserved effects, and common technology shocks that potentially invoke omitted variable bias in the effects of liability regimes on the propensity to patent. Our investigation reveals that liability regimes combined with damage caps, broad statutory excuses, and reversed burden of proof have a strong positive effect on the firm-level patent stock and a negative effect upon EPO patent validation rate. The evidence suggests that not all liability rules and related litigation procedures are created equal. Firms are systematically more likely to hold (firm-level patent stock) valid patents at the EPO when the liability and litigation rules are not complex and when the damage cap, broad statutory excuses, and reversed burden of proof are introduced.

Jezik:Angleški jezik
Ključne besede:medications, patents, administrative litigation, tort law, liability, litigation, propensity to patent, transaction costs
Vrsta gradiva:Članek v reviji (dk_c)
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:EF - Ekonomska fakulteta
Leto izida:2021
Št. strani:18 str.
Številčenje:Vol. 11, iss. 2
UDK:346
ISSN pri članku:2158-2440
DOI:10.1177/21582440211009470 Povezava se odpre v novem oknu
COBISS.SI-ID:25110019 Povezava se odpre v novem oknu
Število ogledov:193
Število prenosov:114
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
 
Skupna ocena:(0 glasov)
Vaša ocena:Ocenjevanje je dovoljeno samo prijavljenim uporabnikom.
:
Objavi na:AddThis
AddThis uporablja piškotke, za katere potrebujemo vaše privoljenje.
Uredi privoljenje...

Gradivo je del revije

Naslov:SAGE open
Založnik:SAGE Publications
ISSN:2158-2440
COBISS.SI-ID:2586967 Povezava se odpre v novem oknu

Gradivo je financirano iz projekta

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije (ARRS)
Program financ.:Raziskovalni program
Številka projekta:P5-0128
Naslov:Izzivi vključujočega in trajnostnega razvoja v prevladujoči paradigmi ekonomskih in poslovnih znanosti

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:19.04.2021

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:zdravila, patenti, upravni spor

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Komentarji

Dodaj komentar

Za komentiranje se morate prijaviti.

Komentarji (0)
0 - 0 / 0
 
Ni komentarjev!

Nazaj